Evaluation of the Surgical Outcomes of Breast Oncoplastic Techniques Carried Out by a General Surgical Oncologist

Review began 10/18/2021
Review ended 11/02/2021
Published 11/03/2021

© Copyright 2021

Monib et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Sherif Monib ¹, Ibrahim Elzayat ²

1. Breast Surgery, West Hertfordshire Hospitals National Health Services (NHS) Trust, St. Albans and Watford General Hospitals, London, GBR 2. General Surgery, Aswan University Hospital, Aswan, EGY

Corresponding author: Sherif Monib, sherif.monib@nhs.net

Abstract

Background

With recent advances in different breast cancer treatment modalities, breast conservation surgery (BCS) has gained popularity and has become the mainstay for the treatment of early breast cancer. The model of dedicated breast surgeons working in breast units is standard in some but not all countries. We have aimed to define surgical outcomes of oncoplastic breast surgery carried out by one general surgical oncologist.

Patients and methods

We have conducted a prospective non-randomised case series analysis to assess the oncologic and aesthetic outcome of tissue displacement oncoplastic breast techniques in managing unifocal early-stage breast cancer from January 2019 to January 2020.

One surgical oncologist with 23 years of surgical oncology experience carried out all operations.

Results

We have included 50 female patients treated with variant oncoplastic volume displacement techniques. We have used the round block technique in 20%, the batwing technique in 18%, lateral mammoplasty in 20%, and medial mammoplasty in 2%. We have also carried out wise pattern therapeutic mammoplasty with inferior pedicle in 20% (10 patients), and vertical mammoplasty with superior pedicle in 20% (10 patients).

While 8% of our patients had Clavien-Dindo system grade I Immediate complications, including the surgical site infection and postoperative seroma and haematoma, 2% of patients had grade II complications in the form of partial areola and nipple complex necrosis leading to delayed wound healing requiring secondary suturing. No delayed complications or mortalities were recorded.

Eight per cent of patients required re-excision to clear margins, 74% had excellent results, 24% had good results, and 2% had fair results. In addition, 64% were very satisfied with their results, 32% were satisfied, while 4% were not satisfied with aesthetic results.

Conclusion

Based on our limited number of patients, we have found that tissue displacement oncoplastic techniques carried out by a general surgical oncologist are safe and reliable in providing satisfactory oncological outcomes with a low risk of delaying adjuvant therapy and acceptable aesthetic outcomes.

Categories: General Surgery, Oncology

Keywords: surgical oncology, volume displacement, oncoplastic techniques, breast conservation therapy, breast cancer

Introduction

Breast cancer is one of the most common cancers worldwide and the most common cancer in females, equating to age-standardised incidence rates (ASIRs) of 19.7 breast cancer cases per 100,000 premenopausal women and 152.6 cases per 100,000 postmenopausal women [1]. It is also considered the most common type of cancer among Egyptian women. It accounts for about 38.8% of total malignancies among Egyptian women; it is also one of the leading causes of female mortalities [2].

With surgical innovation, breast conservation therapy (BCT) has gained popularity and has become the primary treatment modality for early breast cancer. It has been proven to have almost equal survival rates and acceptable recurrence rates for early-stage breast cancer treated with breast conservation surgery (BCS)

How to cite this article

Monib S, Elzayat I (November 03, 2021) Evaluation of the Surgical Outcomes of Breast Oncoplastic Techniques Carried Out by a General Surgical Oncologist. Cureus 13(11): e19226. DOI 10.7759/cureus.19226

followed by radiotherapy compared to total mastectomy alone [3].

Breast-conserving oncoplastic techniques are divided into volume displacement and volume replacement techniques: the first is constituted by rotational mammaplasty techniques (glandular rotation mammaplasty, dermoglandular rotation mammaplasty, and tumour adapted mastopexy), the latter by latissimus dorsi flap and lateral thoracic advancement flap [2].

Several studies have demonstrated an increased risk of breast deformity, poor aesthetic outcomes, and patients' satisfaction associated with resection of more than 20% of the breast volume [4]. On the contrary, other studies have reported better outcomes using oncoplastic resection techniques, including favourable aesthetic outcomes and patients' satisfaction, and clear tumour resection margins [5]. In recognition of the recent advances and evidence-based changes in breast cancer management, the European Society of Breast Cancer Specialists (Eusoma) has defined a breast centre (or unit) as the place where breast cancer is diagnosed and treated. It also has to provide all the services necessary, including prevention genetics assessment, treatment of the primary breast cancer as well as metastatic disease, with supportive and palliative care and survivorship, and psychosocial support. Furthermore, to gain recognition, a breast centre must have sufficient capacity to manage at least 150 newly diagnosed breast cancer cases per year [6].

Unfortunately, this is not feasible in all countries especially developing countries where breast cancer is still managed by general surgical oncologists yet with very good outcomes. Since the model of dedicated breast surgeons working in breast units is common in some but not all countries, we have aimed to define surgical outcomes of oncoplastic breast surgery carried out by one general surgical oncologist.

Materials And Methods

Study setting

This study was conducted in Aswan University Hospital, Aswan, Egypt.

Ethical considerations

We have obtained the Ethical Committee approval before conducting the study.

Study design

We have conducted a prospective non randomised case series analysis including consecutive patients treated with BCS carried out by the same surgeon from January 2019 to January 2020. We have included female patients older than 18 who had palpable breast cancers treated with BCS for unifocal T1, T2 (≤ 4 cm) breast cancer. We have excluded patients treated with primary chemotherapy, patients with local recurrence, metastatic disease, and patients who had previous reduction mammaplasty. Patients' demographics, tumour characteristics, and histological findings were included.

All patients had triple assessment including clinical breast examination followed by digital mammogram as well as bilateral breast and axillary ultrasound scan. In addition, magnetic Resonance Imaging (MRI) was carried out for a selective group of patients (mainly patients with invasive lobular carcinoma to rule out multifocal and bilateral disease), and a staging CT scan was carried out for patients with axillary metastasis.

One surgical oncologist with 23 years of surgical oncology experience (General surgery MD and MRCS) carried out all operations. Surgical techniques used included round block, batwing, lateral and medial mammaplasty, as well as wise pattern and vertical mammaplasty.

We assessed immediate complications up to 30 days postoperative and delayed complications up to one year postoperative and graded them according to the Clavien-Dindo system [7]. Six months after the end of the adjuvant radiotherapy, the aesthetic result was assessed by two independent surgical oncologists other than the operating surgeon, using a 5-point score ranging from 1 to 5 [8]. Also, patients were verbally asked if they were very satisfied, satisfied, or not satisfied with their aesthetic results.

Statistical methods

Collected data were organised and statistically analysed using SPSS software statistical computer version 22 (SPSS Inc., Chicago, IL, USA). For quantitative data, the mean, standard deviation (SD), and range were calculated. Qualitative data collected were presented as numbers and percentages.

Results

Patient and tumour characteristics

We have included 50 female patients, the mean age was 52 years SD 7.4 years, 19 patients were premenopausal, and 31 were postmenopausal. The patient's BMI was 27.4 SD 3.7; Bra size was B cup in 4 patients (8%), C cup in 28 patients (56%), D cup in 17 (34%), and DD cup in one patient (2%). All patients

included were patients who presented with palpable breast lesions. The tumour was located in the upper inner quadrant in 22% (11 patients), the upper outer quadrant in 46% (23 patients), the lower outer quadrant in 18% (nine patients), the lower inner quadrant in 10% (five patients), and in the retroareolar region in 4% (two patients) (Table 1).

Patients' demographics	All patients (N=50)
Age	52 years SD 7.4
Weight	76 Kg SD12
BMI	27.4 SD 3.7
Tumour characteristics	
Tumour site:	
Right side	36% (18 patients)
Left side	64% (32 patients)
Upper inner quadrant	22% (11 patients)
Upper outer quadrant	46% (23 patients)
Lower outer quadrant	18% (9 patients)
Lower inner quadrant	10% (5 patients)
Retroareolar region	4% (2 patients)
Tumour size	31mm SD 6
Tumour histological type:	
Invasive ductal carcinoma	92% (46 patients)
Invasive lobular carcinoma. Invasive and DCIS	8% (4 patients)
Invasive disease as well as Ductal carcinoma in situ	12% (6 patients)
Invasive tumour grading:	
Grade I	12% (6 patients)
Grade II	84% (36 patients)
Grade III	4% (8 patients)
Hormonal status:	
RR-PR positive	86% (43 patients)
ER-PR negative	14% (7 patients)
HER2 positive	10% (5 patients)
HER2 negative	90% (45 patients)
Triple-negative	14% (7 patients)
Axillary lymph nodes status:	
Involved	52% (26 patients)
Not involved	48% (24 patients)

TABLE 1: Patients' demographics and tumour characteristics

Histological findings

The mean postoperative specimen weight was 73g SD 17, mean histological tumour size was 31mm SD 6, and final histology revealed that 92% (46 patients) had invasive ductal carcinoma (IDC), 8% (four patients)

invasive lobular carcinoma (ILC). 12% (six patients) had the invasive disease as well as ductal carcinoma in situ (DCIS). Invasive tumour grading was Grade I in 12% (six patients), Grade II in 84% (36 patients), and Grade III in 4% (eight patients).

Eighty-six per cent (43 patients) patients had oestrogen and progesterone positive disease while 14% (seven patients) were oestrogen and progesterone negative, 10% (five patients) had human epidermal growth factor receptor 2 (HER 2) positive, 7% (14 patients) were found to have triple-negative disease, and 52% (26 patients) had involved axillary lymph nodes, while 48% (24 patients) had negative axillary lymph nodes (Table 1).

Treatment

The oncoplastic techniques used included a round block technique in 20% (10 patients), a batwing technique in 18% (nine patients), lateral mammoplasty in 20% (10 patients), medial mammoplasty in 2% (one patient). We have also carried out wise pattern therapeutic mammoplasty with inferior pedicle in 20% (10 patients), and vertical mammoplasty with superior pedicle in 20% (10 patients). Seventy-two per cent (36 patients) had blue dye directed sentinel lymph node biopsy (SLNB), 28% (14 patients) had axillary lymph node clearance (ALNC) at the same time of the breast procedure, while 24% (12 patients) had sentinel lymph node biopsy followed by axillary lymph node clearance due to macrometastasis (Table 1). The mean operative time was 90 minutes SD 25.

Eight per cent (four patients) had Clavien-Dindo system grade I immediate complications, including that 2% (one patient) had surgical site infection which led to minor wound dehiscence, 4% (two patients) had postoperative haematoma treated conservatively, 2% (one patient) had seroma requiring bedside aspiration. In comparison, 2% (one patient) Clavien-Dindo system grade II complication in the form of partial areola and nipple complex necrosis leading to delayed wound healing due to wound dehiscence, which was later treated by secondary suturing, no delayed complications or mortalities were recorded (Table 2) [7].

Surgical treatment	
The mean postoperative specimen weight	73g SD 17
The oncoplastic techniques used included	
Round block technique	20% (10 patients)
Batwing technique	18% (9 patients)
Lateral mammoplasty	20% (10 patients)
Medial mammoplasty	2% (1 patients)
Wise pattern mammoplasty	20% (10 patients)
Vertical mammoplasty	20% (10 patients)
Postoperative complications	
Clavien-Dindo system grade I	8% (4 patient)
Surgical site infection	2% (1 patient)
Postoperative haematoma	4% (2 patients)
Seroma	2% (1 patient)
Clavien-Dindo system grade II	2% (1 patient)
Further surgery	
Re-excision	8% (4 patients)
Contralateral symmetrising breast surgery	2% (1 patient)
Adjuvant treatment	
Chemotherapy	52% (26patients)
Targeted treatment (Herceptin)	10% (5 patients)
Radiotherapy	100% (all patients)
Endocrine treatment	88% (43 patients)

TABLE 2: Treatment modalities

All patients had adjuvant whole breast radiotherapy. In addition, 88% (43 patients) had adjuvant endocrine treatment (selective estrogen receptor modulators [SERMs] or aromatase inhibitors), 52% (26 patients) had chemotherapy, and 10% (five patients) had chemotherapy and Herceptin. Eight per cent (four patients) required re-excision to clear margins, and one patient (2%) required symmetrising breast surgery carried out eight months postoperatively (Table 2).

Follow up

All patients were assessed clinically two weeks, six months and 12 months after surgery. The mean follow up period was 15.5 months SD 5.1.

Aesthetic assessment after six months postoperatively revealed that 74% (37 patients) had excellent results, 24% (12 patients) had good results, and 2% (one patient) had fair results. In addition, 64% (32 patients) were very satisfied with their results, 32% (16 patients) were satisfied, while 4% (two patients) were not satisfied with aesthetic results (Table 3).

Aesthetic assessment	
Excellent results	74% (37 patients)
Good results	24% (12 patients)
Fair results	2% (1 patient)
Patients' satisfaction	
Very satisfied	64% (32 patients)
Satisfied	32% (16 patients)
Not satisfied	4% (2 patients)

TABLE 3: Aesthetic assessment and patients' satisfaction

None of our patients had a local recurrence or metastatic disease, or breast-related mortalities.

Discussion

The European Institute of Oncology in Milan reported that patients who had oncoplastic breast surgery (OPBS) not only experience less level of anxiety but also feel more comfortable viewing their body image. A further evaluation has found a vast majority of women with nipple preservation have reduced mental and emotional stress, improved body image, and overall satisfaction with results of OPBS [9].

With increased pressures for medical care and the increasing number of patients requiring breast cancer treatment, some general surgeons are developing an interest in breast cancer management. Also, some surgical oncologists are dedicating more time to breast cancer than other cancer sites, yet the outcome of these practices is yet to be evaluated. In nearly all the literature available in relation to oncoplastic breast resections, operations were either carried out by breast surgeons or in most cases, surgeons' subspeciality were not mentioned, the fact which might have affected the outcome in many patients, that's why we have clearly stated the surgeon's experience and qualification.

Tumour size in relation to breast size has always dictated the feasibility of breast-conserving surgery. The average tumour size was 31mm in our cohort, with most of our patients with medium-sized breasts. Studies comparing BCS using oncoplastic techniques and standard wide local excision demonstrated that significantly larger tumours were excised using BCS oncoplastic techniques rather than those treated with a standard wide local excision [10,11].

While we have used intraoperative specimen x-ray to assess resection margins status, others have used different modalities. Intraoperative frozen section assessment was the most popular as it shows a sensitivity of 83% and accuracy of 96% compared with paraffin sections examination [5].

It is well recognized that there is no universal concept on the tumour free margin [12]. Our cohort considered radial margins less than 1mm as close margins for both invasive and non-invasive diseases, so 8% of patients required re-excision to clear margins.

No local recurrence or systemic metastasis was reported in this study. This might be attributed to the relatively small number of patients, in addition to the short time of follow-up.

Oncoplastic breast resections are associated with possible postoperative complications, including seroma, hematoma, surgical site infections, wound dehiscence and fat necrosis, and rarely areola and nipple necrosis. There is always a fear of delay of administration of adjuvant treatment essential for the optimal treatment of breast cancer due to postoperative complications. While Rose et al. reported delay of adjuvant treatment in 6% of their cases due to delayed wound healing [13], none of our patients experienced a delay in adjuvant treatment.

Adjuvant radiotherapy carries a small risk of affecting cosmetic outcomes due to breast tissue atrophy and fibrosis as well as skin oedema [3]; hence we evaluated our patients six months postoperatively to assess patients' satisfactions as well as the aesthetic outcome. Cracco et al. achieved satisfactory cosmetic results in about 75% of their cases [14], also Losken et al. reported a 90% satisfaction rate following breast-conserving surgery using oncoplastic techniques followed by radiotherapy [3]. In our cohort, more than 90% of patients were satisfied with their outcome.

In most patients, minor breast difference is not an issue [10]. In contrast, breast asymmetry in shape and size can be a problem in other cases, especially in patients with the preoperative size difference and those requiring large resections. Only one patient (2.0%) required contralateral symmetrising reduction mammoplasty to achieve symmetry in our cohort.

It has been noted that there is a significant variation in several aspects of oncoplastic practice. Tsigonis et al. found in their cohort that when general surgeons were involved in breast cancer management, operative time was definitely prolonged, but patients' oncological outcomes were not affected [15]. In our cohort, operations were carried out by a surgical oncologist rather than a dedicated breast surgeon. Yet, aesthetic and oncological outcomes were not inferior to those carried out by breast surgeons.

As OPBS has become standard of care in the management of breast cancer patients; the Association of Breast Surgery (ABS) in the UK, the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS), and the Oncoplastic Breast Consortium (OPBC) came up with recommendations and guidance on the best breast surgical oncoplastic and reconstructive practice at each stage of a patient's journey, to ensure unified practice as well as best patient's outcomes [16,17].

Limitations of our analysis

We have only included patients with palpable breast lesions as we do not have a well-established breast screening program yet. We did not assess breast density preoperatively which might have affected oncoplastic technique selection. Unfortunately, we did not have the resources for intraoperative frozen section assessment, to assess resection margins or nodal status, but we carried out intraoperative x-ray specimen assessment to assess resection margins.

Conclusions

Breast-conserving surgery using various oncoplastic techniques is now a well-established first treatment line for managing early breast cancer. Yet, patients' outcomes vary in relation to many factors, one of which is the operating surgeon.

Although operations were carried out by a general surgical oncologist rather than a dedicated breast surgeon in our cohort, we reported good cosmetic results and patients' satisfaction, low reoperation and postoperative complication rate, and no delay in adjuvant therapy. However, we suggest further studies with a larger sample size to develop robust data to reach the best patient-related outcomes possible.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Aswan University Hospital, Egypt issued approval 577/11/21. Dr. Ibrahim Elyayat who obtained Ethics Committee is happy to be contacted at ibrahimelzayat@med.aswu.edu.eg if needed. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM: Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. *Lancet Global Health*. 2020, 1:1027-37. [10.1016/S2214-109X\(20\)30215-1](https://doi.org/10.1016/S2214-109X(20)30215-1)
2. Mahmoud MA, Mashal AH: Evaluation of different oncoplastic procedures in the management of breast cancer from an aesthetic point of view. *Egypt J Surg*. 2019, 38:517-30. [10.4103/ejs.ejs_54_19](https://doi.org/10.4103/ejs.ejs_54_19)
3. Losken A, Pinell-White X, Hart AM, Freitas AM, Carlson GW, Styblo TM: The oncoplastic reduction approach to breast conservation therapy: benefits for margin control. *Aesthet Surg J*. 2014, 34:1185-91. [10.1177/1090820X14545618](https://doi.org/10.1177/1090820X14545618)
4. Noguchi M, Yokoi-Noguchi M, Ohno Y, Morioka E, Nakano Y, Kosaka T, Kurita T: Oncoplastic breast conserving surgery: volume replacement vs. volume displacement. *Eur J Surg Oncol*. 2016, 42:926-34. [10.1016/j.ejso.2016.02.248](https://doi.org/10.1016/j.ejso.2016.02.248)
5. Piper M, Peled AW, Sbitany H: Oncoplastic breast surgery: current strategies. *Gland Surg*. 2015, 4:154-63. [10.3978/j.issn.2227-684X.2015.03.01](https://doi.org/10.3978/j.issn.2227-684X.2015.03.01)
6. Biganzoli L, Cardoso F, Beishon M, et al.: The requirements of a specialist breast centre. *Breast*. 2020, 51:65-84. [10.1016/j.breast.2020.02.003](https://doi.org/10.1016/j.breast.2020.02.003)
7. Dindo D: The Clavien-Dindo classification of surgical complications. *Treatment of Postoperative Complications After Digestive Surgery*. 2014 (ed): Springer, London; 13-7. [10.1007/978-1-4471-4354-3_3](https://doi.org/10.1007/978-1-4471-4354-3_3)
8. Dikmans RE, Nene LE, Bouman MB, et al.: The aesthetic items scale: a tool for the evaluation of aesthetic

- outcome after breast reconstruction. *Plast Reconstr Surg Glob Open*. 2017, 5:e1254. [10.1097/GOX.0000000000001254](https://doi.org/10.1097/GOX.0000000000001254)
9. Benson JR, Dumitru D, Malata CM: Oncologic safety of conservative mastectomy in the therapeutic setting. *Gland Surg*. 2016, 5:37-46. [10.3978/j.issn.2227-684X.2015.05.13](https://doi.org/10.3978/j.issn.2227-684X.2015.05.13)
  10. Khawaja S, Saiyed A, Thayabaran D, et al.: A comparison between oncoplastic breast conserving surgery and standard wide local excision: a UK experience. *J Blood Lymph*. 2015, 1:102. [10.4172/2572-4118.1000102](https://doi.org/10.4172/2572-4118.1000102)
  11. Kelemen P, Pukancsik D, Újhelyi M, et al.: Comparison of clinicopathologic, cosmetic and quality of life outcomes in 700 oncoplastic and conventional breast-conserving surgery cases: a single-centre retrospective study. *Eur J Surg Oncol*. 2019, 45:118-24. [10.1016/j.ejso.2018.09.006](https://doi.org/10.1016/j.ejso.2018.09.006)
  12. Yiannakopoulou EC, Mathelin C: Oncoplastic breast conserving surgery and oncological outcome: systematic review. *Eur J Surg Oncol*. 2016, 42:625-30. [10.1016/j.ejso.2016.02.002](https://doi.org/10.1016/j.ejso.2016.02.002)
  13. Rose M, Manjer J, Ringberg A, Svensson H: Surgical strategy, methods of reconstruction, surgical margins and postoperative complications in oncoplastic breast surgery. *Eur J Plast Surg*. 2014, 37:205-14. [10.1007/s00238-013-0922-4](https://doi.org/10.1007/s00238-013-0922-4)
  14. Cracco S, Semprini G, Cattin F, et al.: Impact of intraoperative radiotherapy on cosmetic outcome and complications after oncoplastic breast surgery. *Breast J*. 2015, 21:285-90. [10.1111/tbj.12402](https://doi.org/10.1111/tbj.12402)
  15. Tsigonis AM, Landercasper J, Al-Hamadani M, et al.: Are breast cancer outcomes compromised by general surgical resident participation in the operation?. *J Surg Educ*. 2015, 72:1109-17. [10.1016/j.jsurg.2015.06.011](https://doi.org/10.1016/j.jsurg.2015.06.011)
  16. Baidam A, Bishop H, Boland G, et al.: Oncoplastic breast surgery--a guide to good practice. *Eur J Surg Oncol*. 2007, 33 Suppl 1:S1-23. [10.1016/j.ejso.2007.04.014](https://doi.org/10.1016/j.ejso.2007.04.014)
  17. Weber WP, Morrow M, de Boniface J, et al.: Knowledge gaps in oncoplastic breast surgery. *Lancet Oncol*. 2020, 21:375-85. [10.1016/S1470-2045\(20\)30084-X](https://doi.org/10.1016/S1470-2045(20)30084-X)